CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Walter Quan, Jr., MD Chief of Medical Oncology and Director of Immunotherapy at Cancer Treatment Centers of America- (CTCA) Western Regional Medical Center is presenting new findings that are showing a major benefit to cancer patients.

The Society for Immunotherapy of Cancer (SITC) national meeting is being held in National Harbor, MD November 7-10, 2013. Hundreds of expert doctors from all over the country will attend workshops, learn new techniques and engage in a hot topic symposium.

Dr. Quan will be speaking on two topics, the first is a new treatment that involves a combination chemoimmunotherapy with monthly cycles of 5-Fluorouracil + Interferon-alfa-2b in previously-treated advanced cancer (with CTCA co-authors Dr. Vivek Khemka, Dr. Laura Martel, and Marci Pierog RN). Combination chemoimmunotherapy is a study in which we treated 18 patients who all had had their advanced cancers grow despite at least 2 different types of chemotherapy treatments. The rationale for our chemoimmunotherapy combination (given over 3 days per month) was to use a chemotherapy drug called 5-Fluorouracil to essentially "soften up" the person's cancer to an attack from that patient's immune system which was stimulated by the immune system booster Interferon-alfa-2b. The treatment was well-tolerated with flu-like symptoms such as fever, shivers, and nausea being the most common side effects. One patient with widely spread non-small cell lung cancer has had shrinkage of her cancer, ongoing at over 1 year. Another patient with colon cancer spread to liver and lymph nodes has had shrinkage of his cancer, ongoing at more than 4 months.

The second topic discusses an activity of dose-dense outpatient intravenous Interleukin-2 preceded by famotidine in metastatic clear cell cancer of the kidney (which is based on work done at Loma Linda). This is a study in which the messenger attack protein Interleukin-2 (the immune system's "911" call) was used along with the antihistamine famotidine (which acts like a signal enhancer) to treat people with widely spread kidney cancer as an outpatient. The rationale for this treatment (which was given for 3 days per week for 6 consecutive weeks) is to send wave after wave of super-charged cancer-killing white blood cells to attack a person's kidney cancer.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unraveling the mystery of cancer resistance